Triglyceride lowering drugs: not just icosapent ethyl.

This commentary refers to 'Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies', by P.R. Lawler et al., 2020;41:86-94.